190 related articles for article (PubMed ID: 22322844)
1. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
[TBL] [Abstract][Full Text] [Related]
2. Simultaneously targeting bcl-2 and Akt pathways sensitizes nasopharyngeal carcinoma to tumor necrosis factor-related apoptosis-inducing ligand.
Li SS; Tang QL; Wang SH; Wang S; Yang XM
Cancer Biother Radiopharm; 2012 Feb; 27(1):88-95. PubMed ID: 21936689
[TBL] [Abstract][Full Text] [Related]
3. Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway.
Li SS; Yang S; Wang S; Yang XM; Tang QL; Wang SH
Oncol Rep; 2011 Dec; 26(6):1573-9. PubMed ID: 21850380
[TBL] [Abstract][Full Text] [Related]
4. [Effects of combining tumor necrosis factor related apoptosis-inducing ligand with PI3-K-Akt inhibition on nasopharyngeal carcinoma cell].
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Wang S; Yang XM
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Oct; 46(10):854-8. PubMed ID: 22321426
[TBL] [Abstract][Full Text] [Related]
5. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
[TBL] [Abstract][Full Text] [Related]
6. [Inhibition of PI3K-Akt pathway reverses LMP1 induced TRAIL resistance in nasopharyngeal carcinoma cell].
Li SS; Yang S; Yin DH; Li P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 May; 30(9):744-747. PubMed ID: 29771028
[No Abstract] [Full Text] [Related]
7. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
8. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
[TBL] [Abstract][Full Text] [Related]
10. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
[TBL] [Abstract][Full Text] [Related]
11. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.
Lalaoui N; Morlé A; Mérino D; Jacquemin G; Iessi E; Morizot A; Shirley S; Robert B; Solary E; Garrido C; Micheau O
PLoS One; 2011; 6(5):e19679. PubMed ID: 21625476
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Osaki M; Kase S; Adachi K; Takeda A; Hashimoto K; Ito H
J Cancer Res Clin Oncol; 2004 Jan; 130(1):8-14. PubMed ID: 14605879
[TBL] [Abstract][Full Text] [Related]
14. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
15. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Shin JY; Kim JO; Lee SK; Chae HS; Kang JH
BMC Cancer; 2010 Aug; 10():425. PubMed ID: 20704765
[TBL] [Abstract][Full Text] [Related]
16. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
17. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
Caravatta L; Sancilio S; di Giacomo V; Rana R; Cataldi A; Di Pietro R
J Cell Physiol; 2008 Jan; 214(1):192-200. PubMed ID: 17579344
[TBL] [Abstract][Full Text] [Related]
18. 14-Thienyl methylene matrine (YYJ18), the derivative from matrine, induces apoptosis of human nasopharyngeal carcinoma cells by targeting MAPK and PI3K/Akt pathways in vitro.
Xie M; Yi X; Wang R; Wang L; He G; Zhu M; Qi C; Liu Y; Ye Y; Tan S; Tang A
Cell Physiol Biochem; 2014; 33(5):1475-83. PubMed ID: 24854624
[TBL] [Abstract][Full Text] [Related]
19. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.
Li Q; Ni W; Deng Z; Liu M; She L; Xie Q
Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787
[TBL] [Abstract][Full Text] [Related]
20. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
